N -(2-benzyl)-2-phenylbutanamides as androgen receptor...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S312000, C514S617000, C514S169000, C514S284000, C546S333000, C564S182000, C564S123000, C564S158000

Reexamination Certificate

active

07629367

ABSTRACT:
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

REFERENCES:
patent: 2809965 (1957-10-01), Wheeler et al.
patent: 5607976 (1997-03-01), Englert et al.
patent: 6204293 (2001-03-01), Sebti et al.
patent: 6727239 (2004-04-01), Chabrier de Lassauniere et al.
patent: 6821992 (2004-11-01), Cooke et al.
patent: 7268153 (2007-09-01), Hanney et al.
patent: 2003/0032623 (2003-02-01), Ban et al.
patent: 2004/0053897 (2004-03-01), Dalton et al.
patent: 2004/0087810 (2004-05-01), Dalton et al.
patent: 2004/0122057 (2004-06-01), Banner et al.
patent: 2004/0229904 (2004-11-01), Bunnage et al.
patent: 2005/0009812 (2005-01-01), Seko et al.
patent: 2005/0014763 (2005-01-01), Brown et al.
patent: 2005/0143317 (2005-06-01), Abdel-Meguid et al.
patent: 2005/0234097 (2005-10-01), Brown et al.
patent: 2005/0282872 (2005-12-01), Hangeland et al.
patent: 1 193 248 (2002-04-01), None
patent: 1 438 973 (2004-07-01), None
patent: 1 477 167 (2004-11-01), None
patent: 1-157955 (1987-11-01), None
patent: WO 00 39077 (2000-07-01), None
patent: WO 03 074473 (2003-09-01), None
patent: WO 2004/048335 (2004-06-01), None
patent: WO 2004 108676 (2004-12-01), None
patent: WO 2005 063690 (2005-07-01), None
patent: WO 2005 090287 (2005-09-01), None
H. Shinji, “Novel Heterocyclic Derivative and Production Thereof”, Patent Abstracts of Japan, vol. 013, No. 419, 1989.
C. Jamieson et al., “A Rapid Approach for the Optimisation of Polymer Supported Reagents in Synthesis”, Synlett, No. 11, pp. 1603-1607, 2000.
Database Registry, Abstract, XP-002357059, 2004.
Patent Abstracts of Japan, vol. 13, No. 419, 1989 and JP 01 157955 included (see Item 25 on sheet 1 of 1449 form).
Database Registry, RN 329920-78-7, 2001.
U.S. Appl. No. 11/712,727, filed Mar. 1, 2007.
Ottow, Eckhard et al. “Nonsgteroidal Tissue-selective Androgen Receptor Modulators”, 2008, 249-304,Nuclear Receptor as Drug Targets.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

N -(2-benzyl)-2-phenylbutanamides as androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N -(2-benzyl)-2-phenylbutanamides as androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N -(2-benzyl)-2-phenylbutanamides as androgen receptor... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4095146

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.